OTCMKTS:NWPHF Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis $20.00 0.00 (0.00%) As of 09/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsShort Interest About Newron Pharmaceuticals Stock (OTCMKTS:NWPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Newron Pharmaceuticals alerts:Sign Up Key Stats Today's Range$20.00▼$20.0050-Day Range$20.00▼$20.0052-Week Range$9.10▼$20.00VolumeN/AAverage Volume600 shsMarket Capitalization$357 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing therapies for disorders of the central nervous system. The company’s research and development activities have centered on neurological and psychiatric conditions, including Parkinson’s disease and schizophrenia. Newron’s principal commercial product is safinamide, marketed as Xadago for the treatment of Parkinson’s disease. The medicine is used as an add-on therapy for patients experiencing motor fluctuations and is commercialized in various markets through licensing and distribution arrangements, including a partnership with Zambon. The company is also developing evenamide, an investigational therapy being studied for schizophrenia and related treatment needs. Newron was established in 1998 and has operated internationally through research activities and partnerships. Its corporate headquarters are in Milan, Italy, and Stefan Weber has served as chief executive officer.AI Generated. May Contain Errors. Read More Receive NWPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Newron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NWPHF Stock News HeadlinesEQS-News: Newron presents H1 2026 results and provides corporate updateSeptember 23 at 3:04 PM | markets.ft.comNewron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2026September 22 at 9:58 AM | marketscreener.comMI went to a party with Elon...Josh Baylin, a former Bloomberg tech reporter and ex-SAC Capital analyst, has spent weeks building a paper trail pointing to a new Elon-linked AI device. The FCC recently granted a key approval tied to the project, adding another data point to Baylin's research. His full report, along with the name and ticker of the stock he's watching, is available free.September 24 at 1:00 AM | Stansberry Research (Ad)Newron Pharmaceuticals S p A : presents H1 2026 results and provides corporate updateSeptember 22 at 9:58 AM | marketscreener.comMEQS-News: Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide programSeptember 8, 2026 | markets.ft.comNewron Pharmaceuticals to Participate in June Investor ConferencesMay 28, 2026 | businesswire.comPatient death puts Newron’s late-stage schizophrenia trial on iceApril 30, 2026 | yahoo.comNewron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 StudyApril 29, 2026 | finance.yahoo.comSee More Headlines NWPHF Stock Analysis - Frequently Asked Questions How have NWPHF shares performed this year? Newron Pharmaceuticals' stock was trading at $9.36 at the beginning of the year. Since then, NWPHF shares have increased by 113.7% and is now trading at $20.00. How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:NWPHF CIKN/A Webwww.newron.com Phone(902) 610-3461Fax39-02-6103-4654Employees22Year Founded1999Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.82 million Price / Sales52.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book95.24Miscellaneous Outstanding Shares17,850,000Free FloatN/AMarket Cap$357 million OptionableNot Optionable Beta0.53 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:NWPHF) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Newron Pharmaceuticals S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Newron Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
